Literature DB >> 23042446

Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population.

Pu Li1, Qiang Cao, Peng-Fei Shao, Hong-Zhou Cai, Hai Zhou, Jia-Wei Chen, Chao Qin, Zheng-Dong Zhang, Xiao-Bing Ju, Chang-Jun Yin.   

Abstract

The hypoxia-inducible factor-1α (HIF-1α) plays an important role in regulating angiogenesis, which is essential for tumor growth and metastasis. Genetic variations of HIF1A (coding HIF-1α) have been shown to influence an individual's susceptibility to many human tumors; however, evidence on associations between HIF1A single-nucleotide polymorphisms (SNPs) and prostate cancer (PCa) risk is conflicting. We genotyped three potentially functional polymorphisms in HIF1A (rs11549465, rs11549467 and rs2057482) using the TaqMan method and assessed their associations with PCa risk in a case-control study of 662 PCa patients and 716 controls in a Chinese Han population. Compared with rs11549467 GG genotype, the variant genotypes GA+AA had a significantly increased PCa risk (adjusted odds ratio (OR)=1.70; 95% confidence interval (CI)=1.06-2.72), particularly among older patients (OR=2.01; 95%CI=1.05-3.86), smokers (OR=2.06; 95%CI=1.07-3.99), never drinkers (OR=2.16; 95%CI=1.20-3.86) and patients without a family history of cancer (OR=1.71; 95%CI=1.02-2.89). Furthermore, patients with rs11549467 variant genotypes were associated with a higher Gleason score (OR=2.14; 95%CI=1.22-3.75). No altered PCa risk was associated with the rs11549465 and rs2057482 polymorphism. However, the combined variant genotypes of rs2057482 and rs11549467 were associated with increased PCa risk (OR=2.10; 95%CI=1.23-3.57 among subjects carrying three or more risk alleles). These results suggest that HIF1A polymorphisms may impact PCa susceptibility and progression in the Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042446      PMCID: PMC3720106          DOI: 10.1038/aja.2012.101

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  36 in total

1.  Hypoxia inducible factor-1alpha gene polymorphism G1790A and its interaction with tobacco and alcohol consumptions increase susceptibility to hepatocellular carcinoma.

Authors:  Pei-Ching Hsiao; Mu-Kuan Chen; Shih-Chi Su; Kwo-Chang Ueng; Yi-Chen Chen; Yi-Hsien Hsieh; Yu-Fan Liu; Hsiu-Ting Tsai; Shun-Fa Yang
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Single nucleotide polymorphisms in the hypoxia-inducible factor-1 gene and colorectal cancer risk.

Authors:  Gudrun Knechtel; Joanna Szkandera; Michael Stotz; Günter Hofmann; Uwe Langsenlehner; Peter Krippl; Hellmut Samonigg; Wilfried Renner; Cord Langner; Dadbeh Dehchamani; Armin Gerger
Journal:  Mol Carcinog       Date:  2010-09       Impact factor: 4.784

3.  Association of hypoxia-inducible factor 1-alpha gene polymorphisms and colorectal cancer prognosis.

Authors:  Joanna Szkandera; Gudrun Knechtel; Michael Stotz; Günter Hofmann; Uwe Langsenlehner; Peter Krippl; Tanja Langsenlehner; Dadbeh Dehchamani; Hellmut Samonigg; Wilfried Renner; Armin Gerger
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

4.  Association between the polymorphisms in exon 12 of hypoxia-inducible factor-1alpha and the clinicopathological features of oral squamous cell carcinoma.

Authors:  Tzong-Ming Shieh; Kuo-Wei Chang; Hsi-Feng Tu; Yin-Hua Shih; Shun-Yao Ko; Yuan-Chien Chen; Chung-Ji Liu
Journal:  Oral Oncol       Date:  2010-07-24       Impact factor: 5.337

5.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.

Authors:  P Birner; M Schindl; A Obermair; C Plank; G Breitenecker; G Oberhuber
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

Review 6.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

7.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

Authors:  Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

8.  Synergistic effect and VEGF/HSP70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome.

Authors:  Sana Sfar; Hamadi Saad; Faouzi Mosbah; Lotfi Chouchane
Journal:  Hum Immunol       Date:  2010-02-04       Impact factor: 2.850

9.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

10.  Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis.

Authors:  Tongfeng Zhao; Jing Lv; Jiangpei Zhao; Marius Nzekebaloudou
Journal:  J Exp Clin Cancer Res       Date:  2009-12-27
View more
  24 in total

Review 1.  The association between the rs11549465 polymorphism in the hif-1α gene and cancer risk: a meta-analysis.

Authors:  Yujie Li; Chunyan Li; Hui Shi; Lieming Lou; Pengcheng Liu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  HIF-1α genetic variants and protein expression confer the susceptibility and prognosis of gliomas.

Authors:  Liang Yi; Xuwei Hou; Ji Zhou; Lunshan Xu; Qing Ouyang; Hong Liang; Zhaocong Zheng; Hongjie Chen; Minhui Xu
Journal:  Neuromolecular Med       Date:  2014-06-15       Impact factor: 3.843

3.  Clinicopathological significance of hypoxia-inducible factor-1 alpha polymorphisms in cancers: evidence from a meta-analysis.

Authors:  Xin Hu; Sen Lin; Jun Zheng; Rui Guo; Hao Li; Chao You
Journal:  Tumour Biol       Date:  2013-07-16

Review 4.  HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies.

Authors:  I Gladek; J Ferdin; S Horvat; G A Calin; T Kunej
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

Review 5.  The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis.

Authors:  Xin Hu; Yuan Fang; Jun Zheng; Yazhou He; Xin Zan; Sen Lin; Xi Li; Hao Li; Chao You
Journal:  Tumour Biol       Date:  2013-09-18

6.  Hypoxia-inducible factor-1α (HIF-1α) C1772T polymorphism significantly contributes to the risk of malignancy from a meta-analysis.

Authors:  Gang Wu; Wen-Feng Yan; Yuan-Zeng Zhu; Pei-Chun Sun
Journal:  Tumour Biol       Date:  2014-01-15

7.  HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case-control study.

Authors:  Agnieszka Paradowska-Gorycka; Barbara Stypinska; Andrzej Pawlik; Ewa Haladyj; Katarzyna Romanowska-Próchnicka; Marzena Olesinska
Journal:  Inflamm Res       Date:  2018-02-06       Impact factor: 4.575

8.  Investigation of GLUT1, HIF1α and TBX21 Gene Polymorphisms in Laryngeal Cancer.

Authors:  Cihan Uslu; Mustafa Tüz; Hasan Yasan; Erdoğan Okur
Journal:  Turk Arch Otorhinolaryngol       Date:  2018-06-01

9.  Polymorphic variation of hypoxia inducible factor-1 A (HIF1A) gene might contribute to the development of knee osteoarthritis: a pilot study.

Authors:  Javier Fernández-Torres; Cristina Hernández-Díaz; Rolando Espinosa-Morales; Javier Camacho-Galindo; Norma del Carmen Galindo-Sevilla; Ámbar López-Macay; Yessica Zamudio-Cuevas; Karina Martínez-Flores; Mónica Guadalupe Santamaría-Olmedo; Carlos Pineda; Julio Granados; Gabriela Angélica Martínez-Nava; Marwin Gutiérrez; Alberto G López-Reyes
Journal:  BMC Musculoskelet Disord       Date:  2015-08-21       Impact factor: 2.362

10.  Association between HIF1A P582S and A588T polymorphisms and the risk of urinary cancers: a meta-analysis.

Authors:  Dawei Li; Jikai Liu; Wenhua Zhang; Juchao Ren; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.